10/26/2012

Interleukin-6 treatment did not improve glucose metabolism in the skeletal muscle cells of type 2 diabetes patients compared with those who had normal glucose tolerance, a study indicated. However, IL-6 therapy was associated with increased fatty acid oxidation in both groups, researchers reported in Diabetes.

Related Summaries